[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-hypertension":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,126,0,25,[9,41,69,92,118,153,178,198,229,250,278,303,328,350,374,397,422,443,465,491,517,537,561,590,612],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642046","pulmonary-hypertension-ph-biorepository-for-translational-research-100642046",false,"NCT07647549","Pulmonary Hypertension (PH) Biorepository for Translational Research","* INCLUSION CRITERIA:\n* Provision of signed and dated informed consent form\n* Males and females aged \\>=18 years old\n* Suspected of or diagnosed with PH\n* Able to understand and willing to sign a written informed consent document\n\nEXCLUSION CRITERIA:\n\nAny individual who does not meet all inclusion criteria or is deemed by the local investigator not to be a blood draw candidate will be excluded from participating in this study.","ALL","18 Years","100 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nPulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. It can lead to heart failure and death if not treated. Researchers want to create a repository of blood samples and health information collected from people with PH. They hope to use this information to find better ways to diagnose and treat PH.\n\nObjective:\n\nTo collect blood samples and health information from people suspected of or diagnosed with PH.\n\nEligibility:\n\nPeople aged 18 years and older who have or may have PH.\n\nDesign:\n\nResearchers will collect information from participants medical records.\n\nParticipants will have blood drawn from a vein. About 3 tablespoons will be collected during the study visit. The visit will last about 1 hour.\n\nParticipants may choose to provide new blood samples at follow-up visits. Updated medical information may also be collected.\n\nParticipants may continue to participate as long as the study is ongoing. Participants may opt out of providing new blood samples but remain in the study.\n\nAll study samples will be stored at the National Institutes of Health. Health information will be stored in secure databases.",[25],"Pulmonary Hypertension",[25,27],"Biorepository","NOT_YET_RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":21},"2026-08-26",{"date":36,"type":21},"2036-06-01",{"name":38,"class":39},"National Institutes of Health Clinical Center (CC)","NIH",3,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100504144","phase-3-tadalafil-for-severe-pulmonary-hypertension-due-to-chronic-obstructive-pulmonary-disease-100504144","NCT05844462","Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease","Efficacy of Phosphodiesterase Type 5 Inhibitors in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease","ERASE PH-COPD","Inclusion Criteria:\n\n* Patients ≥ 18 and \\\u003C85 years at inclusion,\n* Dyspnea WHO functional class II to IV,\n* Severe precapillary pulmonary hypertension defined by :\n\n  * a mean pulmonary artery pressure (mPAP) \\>20\n  * associated with normal pulmonary artery wedge pressure (PawP ≤15 mmHg)\n  * and pulmonary vascular resistance (PVR) \\>5 WU\n* COPD diagnosed according to current international recommendation with persistent airflow limitation defined by post-bronchodilatator Forced expiratory volume in 1 second (FEV1) \u002F forced vital capacity (FVC): FEV1\u002FFVC \\\u003C 0.70,\n* Naive patients from PDE5i (sildenafil, tadalafil) PH treatments and who did not receive other specific PH treatment in the last 3 months (bosentan, ambrisentan, macitentan, riociguat, epoprostenol, treprostinil, iloprost),\n* Treatments for COPD need to be stable for at least 1 month before screening visit,\n* Patients who fulfill criteria for a supplemental long-term oxygen therapy need to be supplied sufficiently before study entry. The amount of supplemental oxygen and the delivery method need to be stable for at least 1 month before screening visit,\n* Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period,\n* Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures,\n* Affiliation to a social security regime,\n\nExclusion Criteria:\n\n* Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator,\n* Patients with underlying medical disorders and anticipated life expectancy below 12 months (eg active cancer disease with localized and\u002For metastasized tumor mass),\n* PH not due to chronic respiratory diseases (group 1, 2, 4 or 5 of the clinical classification of PH),\n* Other respiratory diseases: interstitial lung disease, sarcoidosis, lymphangioleiomyomatosis, histiocytosis, or untreated severe sleep apnea disorders,\n* 6-minutes walk distance \\\u003C 50 m or patients unable to perform the 6-minutes walk test,\n* Exacerbation of the COPD requiring hospitalization in the last 8 weeks before screening,\n* COPD with mild (\\> 80% predicted value) or severe (FEV1 \\\u003C30% predicted value) airflow limitation,\n* Patients listed for lung transplantation at the time of inclusion,\n* Systolic left ventricular dysfunction with left ventricular ejection fraction \\\u003C40% on echocardiography,\n* Patient on AME (state medical aid),\n* Participation in another clinical trial during the preceding 3 months and during the study,\n* Pregnant women, or breast-feeding women, or women with childbearing potential not using a combination of condoms and a safe and highly effective contraception method (hormonal contraception with implants or oral contraceptives, or intrauterine devices) and one month after the end of the study, WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal \\[defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \\> 35 mIU\u002FmL\\],\n* Patient under guardianship or curatorship\n\nNon-inclusion criteria related to treatment by tadalafil:\n\n* Contraindication to tadalafil:\n\n  * Severe renal failure (creatinine clearance \\\u003C 30 mL\u002Fmin\u002F1,73 m2)\n  * Severe liver cirrhosis Child-Plugh C\n  * Severe systemic hypotension \\\u003C90\u002F50\n  * Recent myocardial infarction \\\u003C90 days\n  * Medical history of anterior ischemic optic neuropathy\n  * Hypersensitivity to tadalafil or any of the excipients\n* Concomitant use of potent CYP3A4 inhibitors or inducers, soluble guanylate cyclase stimulator (riociguat), other PDE5 inhibitors or nitrates or doxazosin\n* Cardiovascular diseases:\n\n  * Clinically significant aortic and mitral valve disease\n  * Pericardial constriction\n  * Restrictive or congestive cardiomyopathy\n  * Significant left ventricular dysfunction\n  * Life-threatening arrhythmias\n  * Symptomatic coronary artery disease\n  * Uncontrolled hypertension.\n  * Angulation of the penis, cavernosal fibrosis, Peyronie's disease or history of priapism\n* Pulmonary or upper respiratory infection requiring antibiotics, or pulmonary embolism in the last 4 weeks before screening\n* Participation in a respiratory rehabilitation program within the 4 weeks prior to screening or scheduled during the study period\n* Right heart failure necessitating catecholamine support within the 4 weeks prior to screening.","85 Years",{"count":51,"type":21},200,"INTERVENTIONAL",[54],"PHASE3","ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.",[25,57],"Chronic Obstructive Pulmonary Disease","RECRUITING","2026-08-19",{"date":29,"type":32},{"date":62,"type":32},"2024-02-01",{"date":64,"type":21},"2027-12",{"name":66,"class":67},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100603151","understanding-the-effects-of-pulmonary-arterial-hypertension-on-lean-muscle-mass-100603151","NCT07132788","Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass","MUSCLE UP-PH","Inclusion Criteria:\n\n* Signed informed consent prior to initiation of any study mandated procedure.\n* Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification \\[Humbert 2022\\]\n\n  * Idiopathic (IPAH)\n  * Heritable (HPAH)\n  * Drugs or toxins induced\n  * Associated (APAH) with one of the following:\n\n    * Connective tissue disease;\n    * Human immunodeficiency virus (HIV) infection;\n    * Congenital heart disease; or\n    * Portopulmonary hypertension\n* Diagnosis of PAH within 6 months of enrollment or diagnosis of PAH and on stable therapy for 3 months prior to enrollment\n* Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC), prior to enrollment showing:\n\n  * mPAP \\> 20 mmHg; and\n  * PAWP or LVEDP ≤ 15 mmHg\n  * PVR \\> 2 Wood units\n\nExclusion Criteria:\n\n* Prior to enrollment, evidence of moderately severe obstructive ventilator defect with:\n\n  * FEV1\u002FFVC ≤ 5th percentile; and\n  * FEV1 z-score \\\u003C 2.5\n* Prior to enrollment, evidence of severe restrictive defect with\n\n  * TLC \\\u003C 5th percentile\n  * FEV1 z-score \\\u003C 4\n* Prior to enrollment, hospitalization (within 1 week) for decompensated right heart failure\n* More than moderate aortic or mitral valve disease\n* LVEF \\\u003C 40% within 1 year of screening\n* Pregnancy",{"count":77,"type":21},150,"Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. The findings from this study could help identify potentially treatable factors that may improve the overall quality of life and physical functioning of patients with PAH.\n\nSubjects will be asked to attend a baseline visit where the following will be performed:\n\n* Measure your vital signs\n* Undergo a research blood draw, less than 4 tablespoons\n* Provide a urine pregnancy test (if applicable)\n* Review demographics, personal history, and medical history\n* Review current PAH medications\n* Complete questionnaires on how your PAH affects you\n* Complete a test of physical performance\n* Complete a grip strength test\n* Undergo an echocardiogram (Echo)\n* Complete a six-minute walk test\n* Undergo a Chest CT Scan\n* Undergo a scan of your body composition (DXA scan)\n* Obtain a weight and body composition measurement on the InBody Scale Subjects will also complete activity moniotring, two 24-hour diet recalls, and participate in remote follow-up visits every 6 months",[25],[81,82],"pulmonary hypertension","body composition","2026-08-17",{"date":59,"type":32},{"date":86,"type":32},"2025-05-01",{"date":88,"type":21},"2029-07-01",{"name":90,"class":67},"University of Pennsylvania",2,{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":4,"leadSponsor":117,"locationsCount":68},"100188549","natural-history-study-of-biomarkers-in-pulmonary-arterial-hypertension-100188549","NCT01730092","Natural History Study of Biomarkers in Pulmonary Arterial Hypertension","A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension","* ELIGIBILITY:\n\nThe study will enroll subjects with confirmed and suspected NYHA\u002FWHO Group 1 PH (68) as well as age and sex matched control subjects. Subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study. There is no exclusion based on race or sex.\n\nINCLUSION AND EXCLUSION CRITERIA FOR PAH SUBJECTS:\n\nInclusion Criteria:\n\nThe following parameters on RHC are required to meet the hemodynamic definition of PAH (NYHA\u002FWHO Group I PH):\n\n* mean pulmonary artery pressure of \\> 25 mmHg at rest,\n* pulmonary capillary wedge pressure of \\\u003C 15 mmHg (or a left ventricular end-diastolic pressure of \\\u003C 12 mmHg), and\n* pulmonary vascular resistance of \\> 3 Wood units (240 dyn s cm-5).\n\nFor patients with suspected PAH (Group I PH) who have not undergone a RHC and\u002For additional testing to confirm the diagnosis, this testing will be completed as clinically indicated under a procedural consent. If clinically indicated (diagnostic) testing indicates that the subject with suspected PAH does not in fact meet standard criteria for PAH (Group I PH), then the subject will be removed from the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women (all women of childbearing potential will be required to have a screening urine or blood pregnancy test)\n* Age less than 18 years\n* Inability to provide informed written consent for participation in the study\n\nINCLUSION AND EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS:\n\nInclusion Criteria for Control Subjects\n\nAny healthy man or woman who is the appropriate age and sex for matching to a PAH patient\n\n* Must be eligible for MRI and Gadolinium Based MRI studies\n* Must be eligible for CT and Iodine Based Contrast CT studies\n\nExclusion Criteria for Healthy Control Subjects\n\n* Current pregnancy or breastfeeding (All women of childbearing potential will be required to have a screening urine or blood pregnancy test)\n* Electrocardiographic evidence of clinically relevant heart disease\n* Symptoms of coronary or cardiac insufficiency\n* More than one major risk factor for coronary artery disease (excluding age and sex)\n* Obesity (defined as a body mass index \\> 30 kg\u002Fm\\^2)\n* History of underlying conditions\u002Frisk factors associated with pulmonary hypertension such as collagen vascular disease, HIV infection, use of appetite suppressants, chronic liver disease or cirrhosis of the liver, chronic thromboembolic disease, congenital heart defects, hypoxemia and\u002For significant pulmonary parenchymal disease\n* Systemic hypertension that is not well controlled (i.e. blood pressure at the time of screening \\>140\u002F90 mmHg in adults \\\u003C 60 years old or \\>150\u002F90 mmHg in adults 60 years or older) on medications. Subjects taking \\> 2 anti-hypertensive medications will be excluded irrespective of their current blood pressure at time of screening\n* Anemia, thrombocytopenia or coagulopathy\n* Renal insufficiency (defined as an estimated glomerular filtration rate of \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2 of body surface area)\n* Active tobacco use (\\> 6 months) in the past ten years, any tobacco use within 3 months prior to the screening evaluation or any tobacco use prior to completion of the study\n* Inability to provide informed written consent for participation in the study\n* History of recreational drug use with the exception of marijuana (as long as marijuana use was \\> 3 months from the time of study screening).\n\n  * Volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer.\n\nExclusion Criteria for MRI in Healthy Control Subjects and Subjects with PAH\n\nThese contraindications include but are not limited to the following devices or conditions:\n\n1. Implanted cardiac pacemaker or defibrillator\n2. Cochlear Implants\n3. Ocular foreign body (e.g. metal shavings)\n4. Embedded shrapnel fragments\n5. Central nervous system aneurysm clips\n6. Implanted neural stimulator\n7. Any implanted device that is incompatible with MRI\n8. Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and severe dyspnea at rest\n9. Subjects requiring monitored sedation for MRI studies\n10. Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.)\n11. Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.\n\nExclusion Criteria for Gadolinium Based MRI Studies Only:\n\n1. History of severe allergic reaction to gadolinium contrast agents despite pre- medication with diphenhydramine and prednisone\n2. Chronic kidney disease (an estimated glomerular filtration rate of \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2 of body surface area)\n\nExclusion Criteria for Cardiac Computed Tomography in Healthy Control Subjects and Subjects with PAH:\n\n1\\) Subjects with a condition precluding entry into the scanner (e.g. morbid\n\nobesity, claustrophobia, etc.)\n\nExclusion Criteria for Iodine Based Contrast CTA Studies Only:\n\n1. Serum creatinine \\> 1.4 mg\u002FdL\n2. History of multiple myeloma\n3. Use of metformin-containing products less than 24 hours prior to contrast administration\n4. History of significant allergic reaction to CTA contrast agents despite pre-medication with diphenhydramine and prednisone",true,{"count":101,"type":21},270,"Background:\n\n\\- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH.\n\nObjectives:\n\n\\- To study the natural history of PAH.\n\nEligibility:\n\n* Individuals at least 18 years of age who have PAH.\n* Healthy volunteers at least 18 years of age.\n\nDesign:\n\n* Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center. After the first visit, they will return in 6 months and then yearly or every other year for as long as the study continues.\n* The first visit will take up to 3 days. It will involve the following tests:\n* Physical exam and medical history\n* Blood and urine samples\n* Heart and lung function tests and imaging studies\n* Six-minute walk test\n* Questions about exercise and physical activity\n* Healthy volunteers will have only one visit to the Clinical Center, during which they will undergo screening tests, and complete many of the same tests as patients with PAH",[104,25],"Pulmonary Disease",[106,107,108,109,110,111],"Vascular Inflammation","Microarray","Right Ventricular Function","Endothelial Dysfunction","Magnetic Resonance Imaging","Natural History","2026-08-15",{"date":114,"type":32},"2026-08-18",{"date":116,"type":32},"2013-07-15",{"name":38,"class":39},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":126,"targetDuration":4,"studyType":52,"phases":128,"briefSummary":130,"conditions":131,"keywords":139,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":152},"100609422","a-randomized-placebo-procedure-controlled-trial-of-the-enhancor-system-pulmonary-artery-denervation-to-evaluate-safety-and-efficacy-in-patients-with-combined-pre--and-post-capillary-pulmonary-hypertension-associated-with-left-heart-disease-100609422","NCT07214376","A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease","The PULSE-LHD","Inclusion Criteria:\n\n1. Subject is ≥18 and ≤85 years of age\n2. Subject is diagnosed with chronic HF due to left-sided heart disease for at least 6 months prior to screening (regardless of LVEF), and remains symptomatic despite maximally tolerated class I GDMT for left heart failure and CRT as appropriate per US or EU guidelines according to region of enrollment\n3. Subject is clinically stable, defined as:\n\n   * No hospitalizations for heart failure for at least 1 month; no major changes in societal guideline-recommended class I oral GDMT for left heart failure for at least 1 month; no CRT or ICD implant in the prior 3 months; and no anticipated major changes in any HF-GDMT (other than possibly diuretic dose) or planned cardiac rhythm management device implantation after the procedure\n   * SBP is ≥90 and ≤160 mmHg and resting HR is ≥50 and ≤100 bpm (≤110 bpm for atrial fibrillation)\n4. PASP (RVSP) is ≥30 mmHg on the baseline TTE.\n5. Subject has New York Heart Association (NYHA) class II, III or IVa symptoms (IVa is defined as symptoms with minimal exertion or at rest, but the patient is able to ambulate and does not require continuous intravenous medications).\n6. Subject has 6MWD at baseline ranging from 100 to 450 m limited by dyspnea or fatigue and not orthopedic or other non-HF-related issues\n7. Subject has NT-proBNP ≥600 pg\u002FmL for patients with LVEF ≤40% or ≥200 pg\u002FmL for patients with LVEF \\>40% at the time of screening (a central lab will be made available for sites that cannot measure NT-proBNP)\n8. Subject is able and willing to follow all aspects of the research protocol including medication compliance and follow-up visits and testing.\n9. Subject or the subject's legally designated representative signs an IRB\u002FEC approved informed consent form prior to study participation.\n\nExclusion Criteria:\n\n1. Subject has a life expectancy of less than 1 year due to non-cardiovascular causes.\n2. Subject has known hypertrophic cardiomyopathy with either left ventricular (LV) outflow tract obstruction or systolic anterior motion (SAM) of the anterior leaflet of the mitral valve; pericardial disease; or infiltrative or active inflammatory myocardial disease, including known amyloidosis\n3. Subject has severe stenosis or regurgitation of any heart valve, moderate or severe stenosis of the aortic valve, or any degree of stenosis of the pulmonic valve\n4. Subject has symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke in the prior 30 days or any prior stroke with a permanent residual deficit with modified Rankin Scale (mRS) score ≥4\n5. Subject has any prior intracranial hemorrhage with or without a residual deficit, or any known intracranial pathology pre-disposing to bleeding (e.g. mass, AV fistula, aneurysm, etc.)\n6. Subjects with a known bleeding diathesis or who will refuse blood transfusions\n7. Subjects allergic to heparin (including heparin induced thrombocytopenia), unless bivalirudin or argatroban can be used for procedural anticoagulation\n8. Subjects with life threatening allergy to contrast dye that cannot be adequately pre-medicated, or any prior contrast-related anaphylaxis\n9. Subject has congenital heart disease other than mitral valve prolapse or a PFO\n10. Subject had coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the prior 6 months or is anticipated to undergo CABG or PCI within 12 months after randomization.\n11. Subject has any pacemaker with an intracardiac sensing or pacing lead or wire implanted in the prior 3 months, or CardioMEMS HF System or other intracardiac pressure monitoring system, or cardiac contractility modulation system or baroreceptor activation therapy implanted within the prior 3 months, or any plans to implant any of these devices within 12 months after the procedure.\n12. Subject has undergone atrial fibrillation ablation within the prior 6 months or is anticipated to undergo atrial fibrillation ablation within 12 months after randomization.\n13. Subject has undergone heart valve surgery or transcatheter valve intervention within the prior 6 months or is anticipated to undergo heart valve surgery or transcatheter valve intervention (e.g., valve repair or replacement, valvuloplasty) within 12 months after randomization.\n14. Subject has any tricuspid or pulmonic valve implants (implanted annuloplasty rings are allowed).\n15. Subject has an inferior vena cava (IVC) filter implant.\n16. Subject has received a prior heart or heart-lung transplantation or is listed for heart or heart-lung transplantation or is anticipated to receive a ventricular assist device (VAD) implant within 6 months after randomization.\n17. Subjects with intracardiac thrombus on TTE.\n18. Subjects with pericardial effusion ≥10 mm on TTE\n19. Subject's PH is predominantly due to WHO Group 1, 3, 4, or 5. Note: Multifactorial features of PH may be present, but the predominant diagnosis must be WHO Group 2 CpcPH.\n20. Subject has been treated with any group 1 PAH-targeted drugs, including sotatercept, within the prior month or is planned to receive such therapy after randomization.\n21. Subject is anticipated to undergo any surgery within 6 months after randomization (other than minor surgeries requiring only local anesthesia).\n22. Subject has severe renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2 by the CKD-EPI formula, or on dialysis).\n23. Subject has severe liver insufficiency (Child-Pugh classification C).\n24. Subject has platelet count \\\u003C100 × 109\u002FL.\n25. Subject has systemic inflammatory or other disease requiring long-term use of oral glucocorticoids or immunosuppressants.\n26. Subject has active infection requiring oral or intravenous antibiotics.\n27. Subject has a body mass index (BMI) \\>45 kg\u002Fm².\n28. Subjects with severe respiratory disease, defined as any disorder of the respiratory system with diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C40% AND total lung capacity (TLC) \\\u003C60% AND forced expiratory volume in one second (FEV1) \\\u003C70% by plethysmography; OR who require ambulatory or long-term oxygen therapy\n29. Subject has known severe untreated sleep apnea. Note: Subjects with sleep apnea treated with CPAP\u002FBiPAP for at least the prior 3 months are not excluded.\n30. Subjects with pulmonary embolism or deep vein thrombosis in the prior 6 months.\n31. Subject is a pregnant or breastfeeding woman, or a woman planning to become pregnant within one year. Women of child-bearing potential must have a negative pregnancy test within 1 week of randomization.\n32. Subject is participating in another clinical trial of an investigational drug or device that has not reached its primary endpoint.\n33. Subject has severe cachexia\u002Ffrailty, substance abuse, or any other condition that the investigator believes may affect the subject's ability to comply with or complete all the study requirements including follow-up visits.\n34. Subject is a member of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, children, impoverished persons, persons in prisons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations may also include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.",{"count":127,"type":21},750,[129],"NA","The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease (LHD). This randomized control trial will compare the investigational device (The Enhancor System) to control (medical therapy.)\n\nParticipants who will consist of patients with chronic heart failure (HF) who are receiving maximally tolerated guideline-directed medical therapy (GDMT) for left heart failure, are clinically stable, and who have been diagnosed with CpcPH by right heart catheterization (RHC), will be treated with PADN and followed for 3 years.",[25,132,133,134,135,136,137,138],"Heart Failure With Reduced Ejection Fraction","Hypertension","Vascular Diseases","Cardiovascular Diseases","Heart Failure","Heart Failure With Preserved Ejection Fraction","Heart Failure With Mid Range Ejection Fraction",[140,141,136,81,142],"Pulmonary Artery Denervation","Pulmonary Hypertension Due to Left Heart Disease","left heart failure","2026-08-14",{"date":114,"type":32},{"date":146,"type":21},"2026-07-30",{"date":148,"type":21},"2031-12-31",{"name":150,"class":151},"Pulnovo Medical, Inc.","INDUSTRY",6,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":52,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100606732","phase-3-efficacy-and-safety-study-of-treprostinil-palmitil-inhalation-powder-tpip-in-participants-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100606732","NCT07179380","Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","PALM-ILD","Inclusion Criteria\n\n* Diagnosis of PH World Health Organisation (WHO) Group 3 associated with ILD \\[including but not limited to idiopathic interstitial pneumonia (IIP), chronic hypersensitivity pneumonitis (HSP), connective tissue disease-associated interstitial lung disease (CTD-ILD), combined pulmonary fibrosis and emphysema (CPFE)\\].\n* Confirmation of fibrotic interstitial lung disease by centrally overread computed tomography (CT) scan performed at Screening or within prior 12 months.\n* PH confirmed by right heart catheterization (RHC) at Screening or within 12 months prior to Screening, with the following hemodynamic findings:\n\n  * Mean pulmonary arterial pressure (mPAP) \\>20 millimetre of mercury (mmHg) and\n  * Pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg and\n  * Pulmonary vascular resistance (PVR) ≥4 wood units (WU).\n* 6 Minute walking distance (6MWD) ≥100 and ≤500 meters at two 6MWTs at Screening performed at least 4 hours apart, with the difference between the 2 distances ≤15%.\n* Participants receiving chronic medication for underlying disease (e.g., antifibrotic, immunomodulators, immunosuppressants, etc.) and\u002For phosphodiesterase 5 (PDE5) inhibitors, should be on this treatment for ≥90 days and on a stable dose for ≥30 days prior to Screening.\n* Capable of giving signed informed consent as described in Section 10.1.5 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion criteria\n\n* Diagnosis of Pulmonary Hypertension WHO Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease.\n* Primary diagnosis of chronic obstructive pulmonary disease (COPD) and\u002For forced expiratory volume in 1 second (FEV1)\u002FFVC \\\u003C0.7 (based on screening or historical spirometry within the prior 6 months).\n* Clinically significant left heart disease:\n\n  * evidence of clinically significant left-sided valvular heart disease,\n  * left ventricular failure with left ventricular ejection fraction (LVEF) \\\u003C45%, or diagnosis of heart failure with preserved ejection fraction (HFpEF)\n  * echocardiography findings at Screening suggestive for postcapillary PH\n  * unstable ischemic heart disease\n  * unstable arrhythmia, including uncontrolled atrial fibrillation (rate-controlled arrhythmia or paroxysmal atrial fibrillation is allowed)\n* Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism.\n* Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine).\n* Current use of cigarettes or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes either every day or some days.\n* Current use of inhaled marijuana, recreational or medical (current use defined as used at least one or more times during the past 30 days prior to Screening) or expected use during the study.\n* Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and\u002For insufficiently understood disease and\u002For may present an unreasonable risk to the study participant as a result of his\u002Fher participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial.\n\nNote: Other protocol defined inclusion\u002Fexclusion criteria may apply.",{"count":162,"type":21},344,[54],"The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.",[25,166],"Interstitial Lung Disease",[81,168],"interstitial lung disease","2026-08-13",{"date":143,"type":32},{"date":172,"type":32},"2026-01-07",{"date":174,"type":21},"2028-12-30",{"name":176,"class":151},"Insmed Incorporated",145,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":52,"phases":186,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":68},"100602459","phase-1-study-of-hs235-in-obese-patients-with-pulmonary-hypertension-and-heart-failure-with-preserved-ejection-fraction-hfpef-100602459","NCT07123779","HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)","Phase 1b\u002F2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Obese Participants With Pulmonary Hypertension and HFpEF","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if they meet at least all the following criteria:\n\n1. Male or female, ≥ 18 years of age.\n2. \\[Sub-population A only - using a remote PAP sensor\\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening.\n\n   Hemodynamic evidence of PH with:\n   1. mPAP ≥ 25 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,\n   2. dPAP ≥ 15 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.\n3. \\[Sub-population B only - without a remote PAP sensor\\]\n\n   Hemodynamic evidence of PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:\n   1. PVR ≥ 240 dyn\\*sec\u002Fcm5 or ≥ 3 WU, and\n   2. mPAP \\> 20 mmHg, and\n   3. PAWP \\> 15 mmHg but \\\u003C 30 mmHg, and\n   4. dPAP ≥ 15 mmHg.\n4. Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \\\u003C 45% during the 2 years preceding Screening..\n5. New York Heart Association (NYHA) class II or III heart failure symptoms.\n6. Stable diuretic regimen during the screening period.\n7. Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \\\u003C 90 at screening.\n8. 6-minute walking distance (6MWD) ≥ 100 m at screening.\n9. Body mass index ≥ 30 to ≤ 50 kg\u002Fm2 and Body weight ≤140 kg.\n10. Ability to adhere to study visit schedule and understand and comply with all protocol requirements.\n\nExclusion Criteria:\n\n1. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.\n2. Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening.\n3. Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening.\n4. Planned cardiovascular revascularization or planned implantation of CRT device.\n5. History of heart transplant or on heart transplant list.\n6. History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening.\n7. Systemic hypotension or uncontrolled systemic hypertension.\n8. History of Pericardial constriction or hypertrophic cardiomyopathy.\n9. History of significant valvular stenosis or regurgitation.\n10. Participants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or mild obstructive sleep apnea (OSA).",{"count":5,"type":21},[187,188],"PHASE1","PHASE2","Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction",[25,137],{"date":83,"type":32},{"date":193,"type":21},"2026-08",{"date":195,"type":21},"2030-01",{"name":197,"class":151},"35Pharma Inc",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":16,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":52,"phases":210,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":40},"100334119","phase-2-autologous-stem-cell-transplantation-in-patients-with-systemic-sclerosis-100334119","NCT03630211","Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)","SSc","Cohort 1: Children, Adolescents and Young Adults (Cohort 1)\n\nInclusion:\n\nIndividuals must meet all the following criteria to be eligible for this study.\n\n1. Patient, parent, or legal guardian must have given written informed consent. For patients ≥ 168 years of age who are developmentally able, assent or affirmation will be obtained.\n2. Age 8-24, inclusive, at time of consent.\n3. Diagnosed with Systemic Sclerosis (SSc) at the age of ≤19.\n4. Failure to respond, specifically no improvement or progression of disease, to at least 2 disease-modifying antirheumatic drugs (DMARDS) within 12 months of consent with any of the following conditions:\n\n   1. Progression of skin thickening over the past 6 months or Modified Rodnan skin score (mRSS) ≥ 20\n   2. Progression of ILD within 18 months prior to consent. Progression to be determined by either of the following:\n\n      * CT scan showing increased ground glass opacities or reticulations OR\n      * Pulmonary function testing (PFTs) showing a decrease in FVC% or DLCO% predicted value of ≥10%.\n   3. Myositis - CPK \\> 2x upper limit of normal or MRI consistent with myositis\n   4. Childhood Myositis Assessment Score \\\u003C 30\n   5. Arthritis\n   6. Digital tip ulcerations\n5. Cardiology clearance to undergo stem cell transplantation (documented in subject's medical chart)\n6. Negative for human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, all confirmed by PCR testing.\n7. Negative pregnancy test for females. who have reached menarche.\n\n87\\. All females of childbearing potential and sexually active males must agree to use an FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause a birth defect.\n\nExclusion:\n\nIndividuals who meet any of these criteria are not eligible for this study.\n\n1. FVC \\\u003C35%, determined by pulmonary function tests for those able to complete spirometry adequately (per investigator's determination)\n2. O2 sat \\\u003C92% at rest in room air\n3. Estimated CrCl \\\u003C40 mL\u002Fmin,using Cockcroft-Gault formula based on actual body weight.\n4. Active, untreated SSc renal crisis at the time of consent.\n5. ALT \\> 4x upper limit of normal.\n6. Active, uncontrolled infection that would be a contraindication to safe use of high-dose immunosuppressive therapy or cyclophosphamide.\n7. Hematologic abnormalities as defined by any of the following peripheral blood counts:\n\n   1. ANC \\\u003C 1500 cell\u002FµL.\n   2. Platelets \\\u003C 100,000 cells\u002F µL.\n   3. Hemoglobin \\\u003C 9.0 g\u002FdL.\n8. Malignancy within 2 years prior to enrollment, excluding adequately treated squamous cell cancer, basal cell carcinoma or carcinoma in situ. Treatment should have been completed with cure\u002Fremission status documented for at least 2 years.\n9. Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n\nCohort 2 for Adults\n\nInclusion:\n\nIndividuals must meet all the following criteria to be eligible for this study.\n\n1. Patient, parent, or legal guardian must have given written informed consent. For patients ≥ 16 years of age who are developmentally able, assent or affirmation will be obtained.\n2. Age 1618-705560, inclusive, at time of consent. Patients up to age 24, diagnosed with SSc at age ≤ 19, will be included in Cohort 1 and evaluated according to the Pediatric and Young Adult criteria listed in sections 3.1.1 and 3.1.2.\n3. Diagnosed with Systemic Sclerosis (SSc), according to the 2013 ACR\u002FEULAR criteria (van den Hoogen et al., 2013).\n4. All patients must meet either the following skin or ILD criteria. Disease duration is defined as time from first non-Raynaud symptom.\n\n   Skin Criteria: Diffuse SSc, defined by presence of proximal skin thickening and:\n\n   A. If disease duration is of \\\u003C2 years, patients must have a calculated mortality risk prediction score which places them in the intermediate or high- risk category (Domsic et al., 2016). Refer to Appendix 5 for calculation criteria.\n\n   B. If disease duration is of \\>2 years, patients must have evidence of active cutaneous disease based upon 1) a worsening Modified Rodnan Skin Score (MRSS) in the preceding three months or 2) the presence of palpable tendon friction rubs.\n\n   ILD Criteria:\n\n   A. The presence of recognized fibrosis on imaging of \\\u003C2 years AND either \\> 10% of lung involvement by CT scan or FVC% pred \\\u003C80% or B. Fibrosis on imaging of any duration with a decline in FVC% pred of ≥10% over the preceding 12-18 months.\n5. Negative for human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, all confirmed by PCR testing.\n6. Negative pregnancy test for females.\n7. All females of childbearing potential and sexually active males must agree to use an FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause a birth defect.\n\nExclusion Criteria Individuals who meet any of these criteria are not eligible for this study.\n\n1. Moderate to severe cardiac involvement defined by any of the following:\n\n   1. New York Heart Association classification of heart failure ≥3.\n   2. Left ventricular ejection fraction (LVEF) \\\u003C50% as determined by cardiac MRI.\n   3. Significant pulmonary hypertension, for subjects ≥ 18 years of age, defined as mean PASP ≥30 mmHg determined by right heart catheterization, or for subjects ≤ 17 years of age, defined as mean PASP \\>45 mmHg, determined by echocardiogram.\n   4. Atrial tachycardia, atrial fibrillation or atrial flutter of ≥1-minute duration, determined by electrocardiogram (EKG) or, cardiac event monitor and\u002For implanted loop recorder (if applicable), or on anti-arrhythmic therapy for the arrhythmias listed above.\n   5. Ventricular tachycardia of ≥6 beats at rate of ≥100 beats per minute, determined by EKG or, cardiac event monitor and\u002For implanted loop recorder (if applicable), or on an anti-arrhythmic therapy for any ventricular arrhythmia.\n   6. Left bundle branch block, bifascicular heart block, Mobitz 2 heart block, complete heart block or infarction pattern as determined by EKG or, cardiac event monitor and\u002For implanted loop recorder\n   7. Presence of pacemaker or implantable cardioverter defibrillator.\n2. Moderate to severe pulmonary involvement defined by any of the following:\n\n   1. Hemoglobin-corrected DLCO \\\u003C45%, determined by pulmonary function tests.\n   2. FVC \\\u003C45%, determined by pulmonary function tests.\n   3. pO2 \\\u003C70 mmHg, determined by an arterial blood gas (not applicable for subjects ≤17 years of age).\n   4. pCO2 ≥45 without supplemental O2 determined by an arterial blood gas (not applicable for subjects ≤17 years of age).\n   5. O2 sat \\\u003C92% at rest without supplemental O2, determined by an arterial blood gas (not applicable for subjects ≤17 years of age).\n   6. Six-minute walk (6MW) results \\\u003C400 feet.\n3. Steroid therapy defined by either of the following:\n\n   1. Subjects who received \\> 10 mg\u002Fday prednisone or equivalent within 30 days prior to start of conditioning regimen on Day -21.\n   2. Subjects who have been treated for concurrent illnesses (eg, asthma) with the equivalent of prednisone 1 mg\u002Fkg\u002Fday or its equivalent for \\> 5 days on \\> 2 occasions during the previous 12 months (prior to conditioning) or \\> 1 occasion in the prior 6 months (prior to conditioning).\n4. Estimated CrCl \\\u003C40 mL\u002Fmin,using Cockcroft-Gault formula based on actual body weight.\n5. Serum creatinine \\>2.0 mg\u002FdL.\n6. Active, untreated SSc renal crisis at the time of consent.\n7. Dependence on nutritional supplementation\u002Fhyperalimentation.\n8. Active gastric antral vascular ectasia (GAVE), defined by a decrease in hemoglobin greater than 1 g\u002FdL in the preceding 60 days, attributed to GAVE.\n9. Active hepatitis defined by any of the following:\n\n   1. AST \\> 2x upper limit of normal.\n   2. ALT \\> 2x upper limit of normal.\n   3. Bilirubin \\>2x upper limit of normal.\n10. Evidence of moderate to severe periportal fibrosis, determined by liver biopsy, if applicable.\n11. Active, uncontrolled infection that would be a contraindication to safe use of high-dose immunosuppressive therapy or cyclophosphamide.\n12. Hematologic abnormalities as defined by any of the following peripheral blood counts:\n\n    1. ANC \\\u003C 1500 cell\u002FµL.\n    2. Platelets \\\u003C 100,000 cells\u002F µL.\n    3. Hemoglobin \\\u003C 9.0 g\u002FdL.\n13. Evidence of myelodysplasia (MDS), confirmed by bone marrow aspirate, if applicable.\n14. Malignancy within 2 years prior to enrollment, excluding adequately treated squamous cell cancer, basal cell carcinoma or carcinoma in situ. Treatment should have been completed with cure\u002Fremission status documented for at least 2 years, with the exception of hormonal therapy for breast cancer.\n15. Females who are pregnant or who are lactating.\n16. Tobacco use, by subject admission, within previous 4 weeks of time of consent.\n17. History of sensitivity to murine proteins or E. coli proteins.\n18. Known history of substance abuse, determined by medical record or subject admission, within 6 months of time of consent.\n19. Patient with systemic reaction to anti-thymocyte globulin or any other equine gamma globulin preparation\n20. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.","8 Years","60 Years",{"count":209,"type":21},8,[188],"The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.",[213,214,166,25],"Systemic Sclerosis","Diffuse Sclerosis Systemic",[216,213,217,166,218,25,219,220],"Stem Cell Transplantation","Scleroderma","ILD (Interstitial Lung Disease)","BMT ( bone marrow transplantation)","Autologous","2026-08-12",{"date":143,"type":32},{"date":224,"type":32},"2018-07-31",{"date":226,"type":21},"2028-08-01",{"name":228,"class":67},"Paul Szabolcs",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":52,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},"100610934","phase-3-an-open-label-extension-study-of-treprostinil-palmitil-inhalation-powder-tpip-in-participants-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100610934","NCT07234032","An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria\n\n* Participants who have completed the lead-in PH-ILD TPIP Study INS1009-311 (NCT07179380).\n* Capable of giving signed informed consent that includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Agree not to participate in any other interventional trials or use investigational drugs or devices while participating in the INS1009-312 study.\n\nExclusion Criteria\n\n* Participants who experienced any adverse events (AEs) evaluated as causally related to TPIP by the Investigator in a lead-in study, which in the opinion of the Investigator, could pose an unreasonable risk of continued treatments for the participant.\n* Current use or expected need for pulmonary arterial hypertension (PAH)-approved therapy, including prostacyclin, prostacyclin analogues or other prostacyclin receptor agonists, endothelin receptor antagonists, and\u002For soluble guanylate cyclase stimulator, or any PH-ILD approved treprostinil therapy. Use of phosphodiesterase 5 inhibitors in line with applicable guidelines is allowed.\n* Diagnosis of Pulmonary Hypertension World Health Organisation (WHO) Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease (including combined pulmonary fibrosis and emphysema).\n* Evidence of left ventricular failure, heart failure with preserved ejection fraction (HFpEF) or postcapillary PH.\n* Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (eg, mannitol, leucine).\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":162,"type":21},[54],"The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).",[25,166],[241],"pulmonary hypertension, interstitial lung disease","2026-08-11",{"date":169,"type":32},{"date":245,"type":32},"2026-07-20",{"date":247,"type":21},"2031-01-22",{"name":176,"class":151},9,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":52,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":68},"100438605","xenon-mri-pulm-hypertension-100438605","NCT04991454","Xenon MRI Pulm Hypertension","Xenon MRI in Pulmonary Hypertension","Jupiter PH","Inclusion Criteria of Cohort 1\n\nSubjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:\n\n1. Outpatients of either gender, Age 18-75\n2. Awaiting a lung transplant\n3. Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, pulmonary vascular resistance ≥ 3 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH), 3 (PH due to chronic lung disease, 4 (PH due to pulmonary artery obstructions), or 5 (PH due to miscellaneous causes)\n4. Willing and giving informed consent and adhere to visit\u002Fprotocol schedules (consent must be given before any study procedures are performed).\n5. Women of childbearing potential must have a negative urine pregnancy test before MRI\n\nExclusion Criteria of Cohort 1\n\nSubjects presenting with any of the following will not be included in the trials:\n\n1. Moderate to severe heart disease (LVEF \\\u003C45%, Severe LV hypertrophy, Moderate to severe valvular disease)\n2. PH due to schistosomiasis\n3. Active cancer\n4. Sickle cell anemia\n5. Prisoners and pregnant women will not be approached for the study\n6. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine)\n7. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements\n\nInclusion Criteria of Cohort 2\n\nSubjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:\n\n1. Treatment naïve or treatment started within the last 3 months\n2. Outpatients of either gender, Age 18-75\n3. WHO functional class (FC) 2-3 symptoms with a diagnosis of group 1 PH (mean pulmonary artery pressures (mPAP) \\> 20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg and pulmonary vascular resistance (PVR) ≥3 WU)\n4. Willing and able to give informed consent and adhere to visit\u002Fprotocol schedules (consent must be given before any study procedures are performed).\n5. Women of childbearing potential must have a negative urine pregnancy test before MRI\n\nExclusion Criteria of Cohort 2\n\nSubjects presenting with any of the following will not be included in the trials:\n\n1. Sarcoidosis\n2. Active cancer\n3. Sickle cell anemia\n4. Liver disease (Childs-Pugh class C)\n5. Any conditions that prevent the performance of 129Xe MRI scans.\n6. Prisoners and pregnant women will not be approached for the study.\n7. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine).\n8. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements","75 Years",{"count":260,"type":21},20,[188],"The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI\u002FMRS) and how these signals change with disease progression or treatment.",[25,264],"Pulmonary Arterial Hypertension",[266,267,268],"Lung Transplant","Xenon","MRI","2026-08-06",{"date":271,"type":32},"2026-08-10",{"date":273,"type":32},"2021-09-01",{"date":275,"type":21},"2027-07-31",{"name":277,"class":67},"Bastiaan Driehuys",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":52,"phases":287,"briefSummary":288,"conditions":289,"keywords":292,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":68},"100650990","self-help-booklets-for-sleep-in-adults-with-pulmonary-hypertension-100650990","NCT07754981","Self-Help Booklets for Sleep in Adults With Pulmonary Hypertension","Development and Pilot Randomised Controlled Trial of a Self-help Sleep Hygiene Intervention to Help Individuals With Pulmonary Hypertension","Inclusion Criteria:\n\nParticipants much be aged 18 years and over.\n\nMust have a diagnosis of PH, which they will be asked to self-report i.e. we will not ask for proof.\n\nMust be able to meet the requirements of the study: give informed consent; complete questionnaires; be literate in English.\n\nMust self-report sleep difficulties. This will be asked as a categorical (yes\u002Fno) question rather than captured through an outcome measure. No sleep measure has been validated for this population. Whilst we can measure sleep, we are unable to quantify difficulties and cannot use a more standardised method of determining a clinical cut off for when a participant may be included or excluded from the study.\n\nExclusion Criteria:\n\nParticipants displaying any significant issues of risk such as self-reported thoughts of harm to self or suicidal thoughts will not be eligible for this study. This is because they are unlikely to benefit from a self-help intervention. this will be asked during a screening questionnaire prior to accessing the consent form. Instead, we will signpost this group to relevant services.",{"count":286,"type":21},60,[129],"The researchers have developed a set of self-help booklets for adults with pulmonary hypertension (PH) who are experiencing sleep problems. The booklets include sleep hygiene advice and are based on a psychological treatment called Cognitive Behavioural Therapy for Insomnia (CBT-I).\n\nCBT-I is a structured, evidence-based treatment for ongoing sleep problems. It helps people understand how their thoughts, behaviours, and daily routines can affect their sleep. It aims to improve sleep quality and help people fall asleep more easily and get back to sleep if they wake during the night.\n\nCBT-I is one of the most effective treatments for ongoing sleep problems. The self-help programme consists of four booklets, which participants will work through at home over four weeks, completing one booklet each week in their own time. The aim of the study is to find out whether the self-help booklets improve sleep quality in people with pulmonary hypertension.\n\nParticipants will be asked to complete questionnaires about their sleep and mental wellbeing, including symptoms of anxiety and depression. Participants will then be randomly allocated to one of two groups. The intervention group will receive the self-help booklets during the study. The wait-list group will receive the booklets at a later date if they are found to be helpful. Having two groups allows the researchers to compare the results and determine whether any improvements in sleep are due to the self-help booklets.\n\nParticipants in the intervention group will also be contacted during the programme to ask about their experiences of using the booklets. Both groups will complete the questionnaires again after four weeks and then again one month later. Participants in the intervention group will also be contacted at the end of the study to discuss their experiences of taking part.",[25,290,291],"Insomnia","Sleep Hygiene",[291,293,294,25,290],"Self-Help","CBT-I","2026-08-04",{"date":271,"type":32},{"date":298,"type":21},"2026-09",{"date":300,"type":21},"2027-03",{"name":302,"class":67},"University of Sheffield",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":52,"phases":313,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":327},"100586150","multi-site-study-of-the-clinical-impact-of-an-ai-assisted-approach-to-referring-patients-with-interstitial-lung-disease-for-diagnostic-evaluation-of-pulmonary-hypertension-100586150","NCT06911632","Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension","MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)","MOMENTOUS","Inclusion Criteria:\n\n* 18 years or older at the time of consent\n* A known diagnosis of interstitial lung disease\n* Diffusing capacity for carbon monoxide (DLCO) \\\u003C30% predicted, collected within 6 months prior to consent\n* Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required\n\nExclusion Criteria:\n\n* A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))\n* A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent\n* LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available\n* Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions\n* A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)\n* Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits\n* There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)\n* There is a medical or social factor that makes the patient a poor candidate for the study and\u002For unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)",{"count":312,"type":21},900,[129],"MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.",[25,316],"Interstitial Lung Disease (ILD)",[25,318],"Interstitial lung disease (ILD)","2026-07-31",{"date":295,"type":32},{"date":322,"type":32},"2025-07-23",{"date":324,"type":21},"2028-07",{"name":326,"class":151},"Tempus AI",32,{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":52,"phases":338,"briefSummary":339,"conditions":340,"keywords":341,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":68},"100575264","phase-1-bridge-to-lung-transplant-with-trans-septal-extra-corporeal-membrane-oxygenation-ecmo-for-right-heart-failure-from-pulmonary-hypertension-100575264","NCT06770023","Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension","A Pilot Study of Transseptal ECMO With the Protek Solo Cannula in Lung Transplant Candidates With Right Heart Failure From Pulmonary Hypertension","Inclusion Criteria\n\nPatients that are listed for lung transplantation and have:\n\n* PH defined as:\n\n  * Group 1 Pulmonary arterial hypertension (PAH): Mean pulmonary artery pressure (PAP) ≥ 20 mm Hg, pulmonary capillary wedge pressure (PCWP) \\\u003C 15 mm Hg, and pulmonary vascular resistance (PVR) ≥ 3 Wood units\n  * Group 3 PH is defined as the presence of chronic lung disease (CLD) and\u002For hypoxia and mean pulmonary artery pressure (PAP) ≥ 20 mm Hg.\n* Secondary PH (WHO Group 3) or diagnosis of primary PH (WHO Group 1) (to include Eisenmenger syndrome).\n* Failing right ventricle function defined as:\n\n  * a cardiac (CI) index \\\u003C 2.2 L\u002Fmin\u002Fm\\^2 despite continuous infusion of high dose inotropes defined as:\n  * Inhaled nitric oxide \\> 20 ppm and one of the following:\n  * Dobutamine \\> 10 ug\u002Fkg\u002Fmin x 15 minutes or\n  * Milrinone \\> 0.5 ug\u002Fkg\u002Fmin x 120 minutes or\n  * Epinephrine \\> 0.5 ug\u002Fkg\u002Fmin x 15 minutes or\n  * Norepinephrine \\> 0.5 ug\u002Fkg\u002Fmin x 15 minutes and have one of the following:\n\n    1. central venous pressure (CVP) \\> 15 mm Hg\n    2. global RV dysfunction on echocardiography defined as one of the following:\n\n       1. a tricuspid annular plane systolic excursion score of \\\u003C14mm\n       2. an RV diameter at base \\>42mm\n       3. RV short-axis or midcavity diameter \\>35mm\n  * Lactate greater than 3 mmol\u002FL\n  * Urine output \\\u003C 0.5 ml\u002Fkg\u002Fhour\n* Age \\> 18 years old\n* BMI \\\u003C35\n* Informed consent signed by self or legally authorized representative.\n\nExclusion Criteria\n\n* INTERMACS 1 patients (Critical cardiogenic shock patient who is \"crashing and burning\", has life-threatening hypotension and rapidly escalating inotropic or pressor support, with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels)\n* End organ failure defined as: hepatic total bilirubin \\>5 mg\u002FdL based on lab data within 24 hours prior to transseptal ECMO initiation; renal creatinine \\>4 mg\u002FdLbased on lab data within the 24 hours prior to transseptal ECMO initiation\n* Evidence of acute neurologic injury\n* Active infection defined as two of the following WBC \\>12,500, positive blood culture, fever\n* RA thrombus\n* Thrombolysis within the previous 30 days or known existing coagulopathy such as thrombocytopenia or hemoglobin diseases such as sickle cell anemia or thalassemia\n* Right heart failure from isolated pulmonary embolism\n* Right heart failure from coronary artery disease or from left heart failure (WHO Type 2)\n* Congenital forms of pulmonary hypertension such as tetralogy of fallot or pulmonary vein stenosis.","80 Years",{"count":337,"type":21},4,[187],"The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.",[266,25],[342],"right heart failure, transseptal, extra-corporeal membrane oxygenation, bridge to transplant",{"date":319,"type":32},{"date":345,"type":21},"2026-12-11",{"date":347,"type":21},"2028-12",{"name":349,"class":67},"Mayo Clinic",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":52,"phases":358,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":68},"100636080","the-benefits-of-home-exercise-in-pulmonary-hypertension-interstitial-lung-disease-100636080","NCT07561034","The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease","Inclusion Criteria:\n\n* Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.\n* Adult patients (\\>18 years old) with right heart catheterization confirmed pulmonary hypertension interstitial lung disease on stable therapy dosing for at least 30 days.\n* Access to a smart phone or email to receive daily messages.\n* Clinically stable by the investigator.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Pulmonary Hypertension Groups 1,2,4,5.\n* Resting tachycardia \\>120 beats\u002Fm during screening.\n* Inability to walk.\n* WHO Functional Class IV\n* Lack of access to email or text messaging.\n* Participating in a rehabilitation program.",{"count":357,"type":21},30,[129],"This study evaluates the effects of a structured home exercise program in participants with pulmonary hypertension associated with interstitial lung disease. Participants will complete a defined exercise regimen over a 16-week period, and functional capacity and patient reported outcomes will be assessed at baseline and after the intervention. The study aims to determine whether a home-based exercise approach is feasible and associated with improvements in functional performance.",[25,166],[362,363,364],"Home Exercise","Exercise Therapy","PH-ILD","2026-07-22",{"date":367,"type":32},"2026-07-24",{"date":369,"type":32},"2026-07-15",{"date":371,"type":21},"2027-05-30",{"name":373,"class":67},"University of Rochester",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":52,"phases":382,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":68},"100541971","phase-2-bioenergetic-effect-of-pioglitazone-in-cld-ph-100541971","NCT06336798","Bioenergetic Effect of Pioglitazone in CLD-PH","Effect of Pioglitazone on Mitochondrial Metabolism in Pulmonary Hypertension Due to Chronic Lung Disease","Inclusion Criteria:\n\n* Provision of a signed and dated informed consent form\n* Stated willingness to comply with all study procedures for the duration of the study\n* Confirmed to have pulmonary hypertension (PH) due to chronic lung disease at screening\n\n  * Pulmonary hypertension is defined based on meeting all three of the following measured at rest during the RHC:\n\n    * Mean pulmonary artery pressure \\>20 mmHg\n    * Pulmonary artery wedge pressure ≤15 mmHg\n    * Pulmonary vascular resistance \\> 2 Wood units\n  * Pulmonary hypertension is classified in Group 3: PH associated with lung diseases and\u002For hypoxia\n* Medications approved for the treatment of pulmonary hypertension must be at a stable dose for at least 30 days\n* Ability to take oral medication and be willing to adhere to the study intervention regimen\n* For females of reproductive potential: agreement to use highly effective contraception during study participation and for an additional 4 weeks after the end of study participation.\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner\n* Agreement to adhere to Lifestyle Considerations (below) throughout the study duration o During this study, participants are asked to arrive in the clinic for study visits in the fasting state. Specifically, participants should abstain from any caloric intake for 6 hours before arrival for the study visit.\n\nExclusion Criteria:\n\n* Diabetes mellitus (type 1 or type 2), present within the preceding 1 year\n* Personal history of symptomatic hypoglycemia within 90 days preceding enrollment\n* Personal outpatient use of pioglitazone, rosiglitazone, metformin, insulin, or other medications for the indication of diabetes within 90 days preceding enrollment\n* History of left ventricular failure (systolic or diastolic)\n* Pulmonary hypertension due to Group 2 PH (PH due to left heart disease)\n* History of prior or active bladder cancer\n* Thrombocytopenia (diagnosis or known platelet count ≤120) within 90 days preceding enrollment\n* Platelet count ≤120 during screening or on the day of enrollment hypertension due to chronic lung disease\n* Cystic fibrosis\n* Pregnancy or lactation\n* Current tobacco use\n* Known allergic reaction to components of the study medication (pioglitazone)\n* Treatment with another investigational drug within 30 days",{"count":260,"type":21},[188],"The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is:\n\n• Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD.\n\nParticipants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo).",[25,385],"Pulmonary Hypertension Due to Lung Diseases",[25,387,388],"Chronic Lung Disease","Pioglitazone","2026-07-21",{"date":365,"type":32},{"date":392,"type":32},"2024-12-17",{"date":394,"type":21},"2028-02",{"name":396,"class":67},"Emory University",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":16,"minAge":403,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":68},"100646088","dynamic-changes-in-right-ventricle-and-pulmonary-artery-coupling-among-copd-patients-with-acute-exacerbation-100646088","NCT07694713","Dynamic Changes in Right Ventricle and Pulmonary Artery Coupling Among COPD Patients With Acute Exacerbation","Inclusion Criteria:\n\n* Patients aged more than 40 years diagnosed with COPD based on pulmonary function tests and admitted to ICU with severe AECOPD. Severe exacerbation is defined according to GOLD 2024 as an exacerbation requiring hospitalization or an emergency department visit, in addition to the acute worsening of respiratory symptoms occurring within ≤14 days.\n\nExclusion Criteria:\n\n* Presence of moderate to severe aortic, mitral, tricuspid, or pulmonary valvular disease\n* A known history of left-sided heart failure before enrolment\n* refusal to participate in the study","40 Years",{"count":405,"type":21},115,"Chronic obstructive pulmonary disease (COPD) is a common, preventable, and manageable disease characterized by persistent respiratory symptoms and airflow limitation. Acute exacerbations of COPD (AECOPD) are major events in the course of the disease and are associated with increased hospital admissions, accelerated decline in lung function, impaired quality of life, and increased mortality. Assessment of exacerbation risk remains a key component of COPD management according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD).\n\nBeyond its respiratory manifestations, COPD may have important cardiovascular consequences. Chronic hypoxia, pulmonary vascular remodeling, inflammation, and increased pulmonary vascular resistance may contribute to elevated pulmonary artery pressures and right ventricular (RV) dysfunction. Pulmonary hypertension associated with chronic lung disease is clinically important because it may worsen symptoms, exercise tolerance, and prognosis.\n\nDuring acute exacerbations, worsening hypoxemia, hypercapnia, dynamic hyperinflation, and increased respiratory workload may further increase pulmonary vascular resistance and RV afterload. Transthoracic echocardiography provides a practical non-invasive method for evaluating right ventricular function and pulmonary hemodynamics through parameters such as tricuspid annular plane systolic excursion (TAPSE), pulmonary artery systolic pressure (PASP), and the TAPSE\u002FPASP ratio, a recognized marker of RV-pulmonary artery coupling.",[408,25],"COPD Exacerbation (AECOPD)",[410,411,412],"COPD","TAPSE","PASP","2026-07-05",{"date":415,"type":32},"2026-07-10",{"date":417,"type":21},"2026-09-01",{"date":419,"type":21},"2028-10-01",{"name":421,"class":67},"Assiut University",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":68},"100643993","correlation-between-ct-pulmonary-angiography-metrics-and-right-heart-catheterization-parameters-in-pre-capillary-pulmonary-hypertension-100643993","NCT07667595","Correlation Between CT Pulmonary Angiography Metrics and Right Heart Catheterization Parameters in Pre-Capillary Pulmonary Hypertension","Inclusion Criteria:\n\n1-Age ≥ 18 years at time of enrolment. 2-Confirmed pre-capillary pulmonary hypertension on RHC performed at Assiut University Hospital: mPAP \\> 20 mmHg AND PAWP ≤ 15 mmHg AND PVR ≥ 2 Wood Units.\n\n3-WHO PH Clinical Group 1 (PAH), Group 3 (PH due to lung disease\u002Fhypoxia), or Group 4 (CTEPH \u002F chronic thromboembolic PH) classification assigned by the PH-MDT.\n\n4-Both CTPA and RHC performed within a maximum interval of 4 weeks. b. Exclusion criteria:\n\n1. WHO PH Group 2 (PH due to left heart disease) or Group 5 (PH with unclear\u002Fmultifactorial mechanisms) .\n2. Active malignancy.\n3. Pregnancy, confirmed or suspected.\n4. Contraindication to iodinated contrast agent: eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² OR documented history of severe anaphylactic contrast reaction.\n5. Inability to sustain breath-hold of ≥ 8 seconds (impairs CTPA quality).\n6. Initiation or dose escalation of pulmonary vasodilator therapy (endothelin receptor antagonist, PDE5 inhibitor, soluble guanylate cyclase stimulator, or prostanoid) in the interval between CTPA and RHC, or within 4 weeks prior to CTPA.\n7. Patient refusal to consent or inability to provide informed consent",{"count":286,"type":21},"Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined by a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest, as confirmed by right heart catheterization (RHC) (1). The global prevalence of PH is estimated at approximately 1% of the adult population, rising to 10% or more in individuals over 65 years of age.Pre-capillary pulmonary hypertension, which includes pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), is characterized by a pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and an elevated pulmonary vascular resistance (PVR) ≥2 Wood units (2)\n\nComputed tomography pulmonary angiography (CTPA) is routinely performed in the diagnostic workup of PH and offers a non invasive alternative that can generate multiple quantitative metrics from a single scan (3). Traditional CTPA metrics, including main pulmonary artery diameter (MPAd), the ratio of MPAd to ascending aortic diameter, central pulmonary arteries, and right ventricular to left ventricular diameter (RV\u002FLV ratio) were previously studied in PH patients (4,5,6) Most existing studies have evaluated CTPA metrics in isolation or within single PH subgroups, limiting generalizability across the broader pre-capillary PH population (7).\n\nTherefore, this study aims to systematically investigate the correlation between multiple quantitative CTPA metrics and key invasive hemodynamic parameters derived from RHC in patients with confirmed pre-capillary pulmonary hypertension",[25,431,432,433],"Precapillary Pulmonary Hypertension","Right Heart Catheterisation","CT Angiography",[435],"CTPA and RHC in precapillary PHTN","2026-06-24",{"date":438,"type":32},"2026-06-25",{"date":440,"type":21},"2026-06-30",{"date":146,"type":21},{"name":421,"class":67},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":335,"enrollmentInfo":451,"targetDuration":453,"studyType":22,"phases":4,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":464},"100526015","an-open-label-prospective-multicenter-study-to-evaluate-safety-and-tolerability-of-dry-powder-inhaled-treprostinil-in-ph-100526015","NCT06129240","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension","ASCENT","Cohort A Key Inclusion Criteria:\n\n1. Males or Females between 18 years to 80 years of age.\n2. Has a confirmed diagnosis of WHO Group 3 PH-ILD based on CT chest imaging performed, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥ 70% and are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following hemodynamic parameters.\n\n   1. i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 30 mmHg.\n\n      OR\n   2. An exploratory subset of subjects with ILD: i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 21 mmHg.\n3. 6-minute walk distance of ≥ 125 meters\n\nCohort A Key Exclusion Criteria:\n\nA Subject is not eligible for inclusion in the study if any of the following criteria apply:\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. History of hemodynamically significant left-sided heart disease.\n3. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.\n4. Initiation of pulmonary rehabilitation.\n\nCohort B Key Inclusion Criteria\n\n1. Male or Females between 18 years to 75 years of age at Screening.\n2. Has a diagnosis of WHO Group 3 PH-ILD confirmed with CT chest imaging performed at the screening visit, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥70%. Subjects are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following documented parameters:\n\n   1. Pulmonary vascular resistance (PVR) ≥3 Wood Units (WU) and\n   2. Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and\n   3. A mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg\n3. Subjects must be on protocol specified dose of inhaled treprostinil QID not at treatment goal, and able to transition from their prescribed dose of inhaled Treprostinil therapy to LIQ861.\n4. 6-minute walk distance of ≥ 200 meters\n\nCohort B Key Exclusion Criteria\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. Inability to titrate inhaled treprostinil above 5 breaths (Tyvaso®) or above 16 mcg Tyvaso DPI®.\n3. History of Bronchospasm with Tyvaso or Tyvaso DPI.\n4. History of persistent moderate asthma or severe asthma.\n5. History of hemodynamically significant left-sided heart disease.\n6. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.",{"count":452,"type":21},80,"52 Weeks","Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \\& 3 PH.",[25,166],{"date":457,"type":32},"2026-06-26",{"date":459,"type":32},"2023-12-28",{"date":461,"type":21},"2028-02-08",{"name":463,"class":151},"Liquidia Technologies, Inc.",23,{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":16,"minAge":206,"maxAge":17,"enrollmentInfo":472,"targetDuration":4,"studyType":52,"phases":473,"briefSummary":474,"conditions":475,"keywords":480,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":68},"100635707","medlypeds-feasibility-study-100635707","NCT07556185","MedlyPeds Feasibility Study","MedlyPeds Feasibility Study: A Mobile, Smartdevice Based Telemonitoring for Pediatric Heart Disease, a Prospective Cohort Study","Inclusion Criteria:\n\n1. Consent provided.\n2. Aged 8-18 years of age.\n3. Ability to comply with using Medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.)\n4. Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons:\n\n   1. Heart failure of any etiology\n   2. Congenital heart disease\n   3. Acquired heart disease (eg. Kawasaki disease, rheumatic heart disease, connective tissue disorders etc)\n   4. Pulmonary hypertension\n   5. Post-cardiac surgery including heart transplant and ventricular assist devices\n\nExclusion Criteria:\n\n1. Unable to read or write in English.\n2. Participating in another clinical trial that may confound the results.\\* \\*Participant may be re-screened for eligibility at a later date.",{"count":357,"type":21},[129],"SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.",[476,477,478,25,479],"Pediatric Heart Failure","Congenital Heart Disease (CHD)","Acquired Heart Disease","Post Cardiac Surgery",[481,482],"Medly","Telemonitoring","2026-06-23",{"date":457,"type":32},{"date":486,"type":21},"2026-07",{"date":488,"type":21},"2029-12",{"name":490,"class":67},"The Hospital for Sick Children",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":501,"conditions":502,"keywords":503,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":68},"100643944","multimodality-rv-phenotyping-for-risk-stratification-and-short-term-outcomes-in-group-1-pah-100643944","NCT07667673","Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH","Multimodality Imaging-Based Right Ventricular Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 Pulmonary Arterial Hypertension: The MIRROR-PAH Study","MIRROR-PAH","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC\u002FERS guidelines\n* Followed at the study center with a diagnosis of PAH\n* Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval\n* Availability of analyzable clinical, imaging, and hemodynamic data\n* Willingness to participate in the study and provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)\n* Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval\n* Incomplete clinical or imaging data preventing analysis\n* Unavailable follow-up data",{"count":500,"type":21},50,"The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening.\n\nAdult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.",[25,264,108],[504,505,506,507,508],"pulmonary arterial hypertension","transthoracic echocardiography","cardiac magnetic resonance imaging","right heart catheterization","risk stratification","2026-06-19",{"date":438,"type":32},{"date":512,"type":32},"2026-05-11",{"date":514,"type":21},"2027-05",{"name":516,"class":67},"Istanbul University - Cerrahpasa",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":335,"enrollmentInfo":523,"targetDuration":4,"studyType":52,"phases":524,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":68},"100644352","early-phase-1-percutaneous-pulmonary-artery-denervation-padn-for-the-treatment-of-pulmonary-hypertension-after-transcatheter-mitral-valve-edge-to-edge-repair-m-teer-a-prospective-cohort-study-100644352","NCT07662655","Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years;\n2. Diagnosed with pulmonary hypertension (defined as mPAP \\>20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months;\n3. No contraindications for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias);\n4. Understands and is willing to sign the informed consent form and authorizes the use of health and study-related information;\n5. Willing to comply with the treatment and follow-up schedule required by the protocol\n\nExclusion Criteria:\n\n1. Cardiac index (CI) \\\u003C 1.5 L\u002Fmin\u002Fm²;\n2. Severe renal insufficiency (creatinine clearance rate (CrCL) \\\u003C 30 mL\u002Fmin);\n3. Left ventricular ejection fraction (EF) \\\u003C30% on echocardiography;\n4. Severe hematological disease or severe bleeding tendency (platelet count \\\u003C10×10⁹\u002FL; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage);\n5. Systemic inflammatory disease, malignancy, tricuspid valve stenosis, pulmonary artery stenosis, and other cardiac diseases requiring surgical or interventional treatment;\n6. Acute systemic infectious disease;\n7. Poor general condition due to various systemic diseases;\n8. Pulmonary veno-occlusive disease;\n9. Cachexia;\n10. Diagnosed with WHO Group 1, 3, 4, or 5 pulmonary hypertension;\n11. Anticipated to undergo other surgical or interventional procedures within 6 months;\n12. Life expectancy \\\u003C12 months;\n13. Allergy to the drugs or metal materials used in the study;\n14. Women who are breastfeeding, pregnant, or planning to become pregnant within one year;\n15. Participation in another drug or medical device clinical trial within 3 months prior to screening;\n16. Any condition deemed unsuitable for participation in this clinical trial by the investigator. \\|",{"count":286,"type":21},[525],"EARLY_PHASE1","this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making",[25,528],"Pulmonary Hypertension Associated With HFpEF","2026-06-17",{"date":483,"type":32},{"date":532,"type":32},"2026-06-06",{"date":534,"type":21},"2028-08-31",{"name":536,"class":67},"Xiamen Cardiovascular Hospital, Xiamen University",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":557,"leadSponsor":559,"locationsCount":337},"100641942","risk-factor-assessment-for-acute-pulmonary-hypertension-crisis-100641942","NCT07653958","Risk Factor Assessment for Acute Pulmonary Hypertension Crisis","Research on the Clinical Risk Factor Assessment System for Acute Pulmonary Hypertension Crisis and Its Mortality","Inclusion Criteria:\n\n* Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter\n* At least once per year of follow-up data collection record\n\nExclusion Criteria:\n\n* Patients with missing baseline or follow-up data\n* Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc.\n* Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc.\n* Receiving medications with significant influence on hemodynamics",{"count":545,"type":21},5000,"The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are:\n\nWhat are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC?\n\nA multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.",[25,548],"Pulmonary Hypertension Crisis",[550,551,552,553],"Pulmonary hypertension","Pulmonary hypertension crisis","Diagnosis","Risk factor",{"date":555,"type":32},"2026-06-22",{"date":529,"type":32},{"date":558,"type":21},"2029-12-31",{"name":560,"class":67},"Peking Union Medical College Hospital",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":16,"minAge":569,"maxAge":570,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":68},"100644448","wearable-assessment-of-thoracic-cardiac-health-and-exercise-performance-trial-prospective-100644448","NCT07663799","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)","WATCH-XP","Inclusion Criteria:\n\n* Age 20 to 70 years old\n* Ability to provide informed consent\n* History of the following cardiovascular conditions:\n* Adult congenital heart disease\n* Pulmonary hypertension\n* Heart failure\n* Coronary artery disease\n* Athletes undergoing cardiovascular assessment\n\nExclusion Criteria:\n\n* Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)\n* Pregnancy\n* Known allergy to components of the investigational product","20 Years","70 Years",{"count":260,"type":21},"Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.\n\nThe Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.\n\nThis investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.",[574,25,136,575,576],"Congenital Heart Disease","Coronary Heart Disease (CHD)","Apple Watch",[578,579,580,581,81],"apple watch","congenital heart disease","heart failure","coronary heart disease","2026-06-16",{"date":483,"type":32},{"date":585,"type":21},"2026-08-01",{"date":587,"type":21},"2028-12-31",{"name":589,"class":67},"The University of Hong Kong",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":99,"sex":16,"minAge":598,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":52,"phases":602,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":608,"leadSponsor":610,"locationsCount":91},"100544776","pulmonary-hypertension-and-oxygen-saturation-targeting-in-preterm-infants-100544776","NCT06373289","Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants","Target Oxygen Saturation Ranges in Infants With Bronchopulmonary Dysplasia Associated Pulmonary Hypertension","PHOX","Inclusion Criteria:\n\n* Between 22w 0\u002F7d and 31w 6\u002F7d gestation at birth\n* Diagnosed with echocardiographic pulmonary hypertension (1) \\>20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index \\>1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg\n* Receiving supplemental oxygen\n* Have mature retinas\n\nExclusion Criteria:\n\n* Major congenital anomalies","1 Month","5 Months",{"count":601,"type":21},39,[129],"Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.",[605,25],"Bronchopulmonary Dysplasia",{"date":529,"type":32},{"date":369,"type":21},{"date":609,"type":21},"2029-12-01",{"name":611,"class":67},"University of Alabama at Birmingham",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":40},"100506361","development-of-an-algorithm-to-detect-pulmonary-hypertension-using-an-electronic-stethoscope-100506361","NCT05873387","Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope","Deep Learning for Algorithmic Detection of Pulmonary Hypertension Using a Combined Digital Stethoscope and Single-lead Electrocardiogram","Inclusion Criteria:\n\n* Patients, ages \\>18 years, referred for complete 2-dimensional echocardiography or right heart catheterization will be screened for inclusion.\n\nExclusion Criteria:\n\n* Patients undergoing limited echocardiography\n* Intubated patients",{"count":620,"type":21},2420,"The major goal of the study is to determine whether phonocardiography (using the Eko DUO stethoscope which can capture a three lead ECG reading) can present features that relate to the presence of PH diagnosed by echocardiography or right heart catheterization (RHC), and therefore have a potential to assist the provider to suspect PH.",[25],[624,625,626,627],"digital stethoscopes","deep learning","auscultation","electrocardiogram","2026-06-15",{"date":529,"type":32},{"date":631,"type":32},"2023-07-12",{"date":633,"type":21},"2027-05-31",{"name":635,"class":151},"Eko Devices, Inc."]